Sahm Adrangi is the creator of Kerrisdale Capital Management. He is also the firm’s Chief Investment Officer. Since founding Kerrisdale Capital Management in 2009, Adrangi has had a strong influence in every area of development. Initially, Adrangi started Kerrisdale Capital Management with just shy of $1 million. These days, however, Kerrisdale currently controls more than $150 million.
He became best known for the findings that he has recently published and for short selling tactics. He is known for publicizing his opinions concerning stocks that he believes the market doesn’t completely understand. Overhyped shorts are a notable example. The firm’s research is extremely important because it defies some long-held misconceptions regarding the future of these companies.
Adrangi first received international recognition as a result of brutally shorting and exposing numerous fraudulent Chinese companies. His findings ended in two of these companies needing to deal with the Securities and Exchange Commission’s enforcement actions.
Over the years that Adrangi has continued to share these findings, many different businesses and industries have been looked into. Today, however, Sahm Adrangi is targeting a few specific sectors with his efforts. The biotechnology sector is now one area where Kerrisdale has built much expertise and shared findings with regards to numerous companies’ development phases. Bavarian Nordic is the most recognizable example or a biotechnology company that he has shared research on.
He kicked off his financial career by working for Deutsche Bank. During his time at Chanin Capital Partners, Mr. Adrangi also did a solid job of advising creditor committees. Sahm Adrangi then stayed several years with Longacre Management.
Sahm Adrangi studied at Yale University , where he got his Bachelor of Arts in Economics. Thanks to his success, Mr. Adrangi has been invited to speak at a variety conferences in the investing world. Adrangi has also been invited for interviews by major television networks and newspapers.